INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/37027

A. CLASSIFICATION OF SUBJECT MATTER
IPC(7) : A61K 31/415, 31/535
US CL : 514/231.5, 394
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 514/231.5, 394

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
None

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Database CA on STN, GlaxoSmithKline, Department of Discovey Medicine, (Research Triangle Park, NC, USA), No. 138:280796, XIA, W. et al., "Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways", abstract, Oncogene 21(41), p.6255-6263, 2002.	1-10
Y	WO 99/35146 A1 (CARTER et al.) 15 July 1999, see abstract and pages 1-15.	1-10
Y	Database CANCERLIT on STN, Department of Pharmaceutical Sciences, University of Maryland-School of Pharmacy, (Baltimore, MD, USA), No. 2002080517, CHEN, X. et al., "Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer", abstract, ONCOGENE, 20(42), pp. 6073-6083, Sep 20, 2001.	1-10
Y	Database CA on STN, Developmental Therapeutics Department, National Cancer Institute, (Bethesda, MD, USA), No. 135:205100, BROGNARD, J. et al., "Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation", abstract, Cancer Research 61(10), pp. 3986-3997, 2001.	1-10

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
03 March 2005 (03.03.2005)

Date of mailing of the international search report
23 MAR 2005

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (703) 305-3230

Authorized officer
Dwayne C. Jones
Telephone No. (703) 308-1123

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/37027

Continuation of B. FIELDS SEARCHED Item 3:
REGISTRY, CA, USPATFULL, BIOSIS, MEDLINE, DRUGU, CANCERLIT chemical name search on REGISTRY with the following terms: wormannin, ly 294002, gw 572016, erb(4a)inhibitor#, pi3k(4a)inhibitor#, akt(4a)inhibitor#